US Patent

US10456414 — Methods for treating HCV

Formulation · Assigned to Gilead Pharmasset LLC · Expires 2032-09-14 · 6y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods and compositions for treating hepatitis C virus infection.

USPTO Abstract

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

Drugs covered by this patent

Patent Metadata

Patent number: US10456414
Jurisdiction: US
Classification: Formulation
Expires: 2032-09-14
Drug substance claim: No
Drug product claim: Yes
Assignee: Gilead Pharmasset LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.